Breaking News Instant updates and real-time market news.

OPNT

Opiant Pharmaceuticals

$15.61

-0.09 (-0.57%)

, EBS

Emergent BioSolutions

$61.56

0.35 (0.57%)

07:25
08/29/18
08/29
07:25
08/29/18
07:25

Cantor sees value in Opiant after Emergent acquires Adapt Pharma

Cantor Fitzgerald analyst Brandon Folkes believes Emergent BioSolutions' (EBS) acquisition of Adapt Pharma underscores the potential for companies addressing the opioid overdose market. Opiant Pharmaceuticals (OPNT) is developing its own opioid overdose nasal spray, OPNT003, which could be of benefit in cases of synthetic opioid overdoses, such as with fentanyl, Folkes tells investors in a research note. He believes Opiant presents an attractive risk/reward at current share levels, "even if it captures only a portion of the growing market opioid overdose market." Folkes keeps an Overweight rating on the shares with a $32 price target.

OPNT

Opiant Pharmaceuticals

$15.61

-0.09 (-0.57%)

EBS

Emergent BioSolutions

$61.56

0.35 (0.57%)

  • 29

    Aug

  • 05

    Sep

  • 05

    Sep

  • 01

    Oct

OPNT Opiant Pharmaceuticals
$15.61

-0.09 (-0.57%)

06/11/18
CANT
06/11/18
INITIATION
Target $32
CANT
Overweight
Opiant Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Cantor initiated Opiant Pharmaceuticals with an Overweight and $32 price target.
06/12/18
CANT
06/12/18
INITIATION
CANT
Cantor expands Specialty Pharmaceuticals coverage with eight names
Cantor Fitzgerald analyst Brandon Folkes last night rolled out coverage on eight names in the Specialty Pharmaceuticals space. He initiated coverage of AcelRx (ACRX), ANI Pharmaceuticals (ANIP), Biohaven Pharmaceutical (BHVN), Collegium Pharmaceutical (COLL), Emergent BioSolutions (EBS), Eagle Pharmaceuticals (EGRX) and Opiant Pharmaceuticals (OPNT) with Overweight ratings. There is still value to be unlocked in these stocks at current valuations with risk/reward profiles that remain to the upside, Folkes told investors in a research note. His top picks are ANI Pharmaceuticals, Emergent BioSolutions and Collegium Pharmaceutical. The analyst rounded out his coverage with a Neutral rating on Momenta (MNTA), saying the recent share rally puts him on the sidelines "for now."
08/10/18
CANT
08/10/18
NO CHANGE
Target $32
CANT
Overweight
Cantor reiterates Overweight on Opiant ahead of pipeline readouts
Cantor Fitzgerald analyst Brandon Folkes reiterates an Overweight rating on Opiant Pharmaceuticals with a $32 price target following the company's Q2 results. The analyst expect investors to begin to appreciate the market potential of Opiant's pipeline, "which should drive the stock higher." The company is developing treatments focused on multiple addictions as well a new product for opioid overdose, Folkes tells investors in a research note titled "Pipeline Readouts in '18 and '19 Make Us Even More Positive on OPNT Stock."
EBS Emergent BioSolutions
$61.56

0.35 (0.57%)

06/13/18
ARGS
06/13/18
INITIATION
Target $62
ARGS
Buy
Emergent BioSolutions initiated with a Buy at Argus
Argus analyst Mike Jaffe initiated Emergent BioSolutions with a Buy rating and a price target of $62, saying the company is on track to generate "solid earnings growth" in the coming years from the demand of its BioThrax vaccine - the only FDA-approved vaccine for anthrax - from the U.S. military. The analyst also cites added benefits from the company's recently acquired products, its pipeline, and its "strong cost controls". Jaffee further states that the valuation for Emergent BioSolutions at 21.1-times his 2018 EPS estimate is attractive relative to the 26.3-times peer average, adding that the discount is too great based on the company's projected earnings growth rate.
06/13/18
06/13/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Liberty Global (LBTYA) initiated with a Sell at Berenberg. 2. Emergent BioSolutions (EBS) initiated with a Buy at Argus. 3. Nine Energy Services (NINE) initiated with a Strong Buy at Raymond James. 4. Can-Fite BioPharma (CANF) assumed with a Buy at H.C. Wainwright. 5. Control4 (CTRL) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/10/18
WELS
08/10/18
NO CHANGE
Target $61
WELS
Market Perform
Emergent BioSolutions acquisition of PaxVax an 'excellent fit,' says Wells Fargo
After Emergent BioSolutions agreed to acquire PaxVax for $270M, Wells Fargo analyst David Maris said the transaction "sounds as though it is an excellent fit" and he is adding $70M in revenues for 2019 and assuming growth of 10% per year, though he thinks that could be conservative given the possible sales synergies. He also raised his price target on Emergent BioSolutions shares to $61 from $56, though he keeps a Market Perform rating on the shares.
08/29/18
CANT
08/29/18
NO CHANGE
Target $62
CANT
Overweight
Emergent acquisition should bridge guidance gap, says Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folkes believes Emergent BioSolutions' acquisition of Adapt Pharma and its opioid overdose product, Narcan nasal spray, should help "bridge the Street's gap" from the current 2020 consensus revenue estimate of $830M to the company's guidance of $1B. The analyst keeps an Overweight rating on Emergent with a $62 price target.

TODAY'S FREE FLY STORIES

CLGX

CoreLogic

$35.67

0.08 (0.22%)

15:07
12/18/18
12/18
15:07
12/18/18
15:07
Hot Stocks
CoreLogic acquires incurance claim solutions firm Symbility Solutions »

Symbility Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$270.49

7.61 (2.89%)

15:06
12/18/18
12/18
15:06
12/18/18
15:06
Periodicals
Netflix testing $3-per-week subscription plan in Europe, BGR reports »

Netflix users in Austria…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$254.76

-0.36 (-0.14%)

, SPX

S&P 500

$0.00

(0.00%)

15:05
12/18/18
12/18
15:05
12/18/18
15:05
Periodicals
Schumer says Dems would 'seriously consider' stopgap funding, Bloomberg says »

Bloomberg cites Chuck…

SPY

SPDR S&P 500 ETF Trust

$254.76

-0.36 (-0.14%)

SPX

S&P 500

$0.00

(0.00%)

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:05
12/18/18
12/18
15:05
12/18/18
15:05
General news
FOMC widely expected to hike rates Wednesday »

FOMC widely expected to…

FDX

FedEx

$184.17

1.97 (1.08%)

15:04
12/18/18
12/18
15:04
12/18/18
15:04
Options
Fedex options imply 9.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

QCOM

Qualcomm

$57.95

0.96 (1.68%)

, AAPL

Apple

$165.48

1.43 (0.87%)

14:59
12/18/18
12/18
14:59
12/18/18
14:59
Periodicals
Qualcomm seeks to extend ban in China to new Apple iPhones, Bloomberg says »

Qualcomm's (QCOM)…

QCOM

Qualcomm

$57.95

0.96 (1.68%)

AAPL

Apple

$165.48

1.43 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$255.30

0.18 (0.07%)

, SPX

S&P 500

$0.00

(0.00%)

14:57
12/18/18
12/18
14:57
12/18/18
14:57
Periodicals
Democrats reject GOP offer to avert shutdown, Washington Post says »

Congressional Republicans…

SPY

SPDR S&P 500 ETF Trust

$255.30

0.18 (0.07%)

SPX

S&P 500

$0.00

(0.00%)

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAT

Mattel

$10.93

-0.25 (-2.24%)

14:55
12/18/18
12/18
14:55
12/18/18
14:55
Options
Mattel put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

14:55
12/18/18
12/18
14:55
12/18/18
14:55
General news
Treasury Action: Treasuries are vulnerable to a knee jerk selloff Wednesday »

Treasury Action:…

MU

Micron

$34.82

0.93 (2.74%)

14:49
12/18/18
12/18
14:49
12/18/18
14:49
Options
Micron options imply 12.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 08

    Jan

MLM

Martin Marietta

$177.29

1.74 (0.99%)

14:46
12/18/18
12/18
14:46
12/18/18
14:46
Hot Stocks
Martin Marietta takes action after 'say on pay' vote, reviewing executive pay »

In connection with Martin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$103.68

0.7 (0.68%)

, AMD

AMD

$19.57

0.74 (3.93%)

14:36
12/18/18
12/18
14:36
12/18/18
14:36
Periodicals
Microsoft next Xbox console is codenamed Anaconda, Verge reports »

Microsoft's (MSFT)…

MSFT

Microsoft

$103.68

0.7 (0.68%)

AMD

AMD

$19.57

0.74 (3.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 03

    Mar

  • 04

    Mar

BIIB

Biogen

$293.41

-19.81 (-6.32%)

, RHHBY

Roche

$0.00

(0.00%)

14:32
12/18/18
12/18
14:32
12/18/18
14:32
Recommendations
Biogen drops after Bernstein sees potential downside of $100 on Q1 risks »

Bernstein analyst Aaron…

BIIB

Biogen

$293.41

-19.81 (-6.32%)

RHHBY

Roche

$0.00

(0.00%)

MYL

Mylan

$29.00

0.15 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 24

    Dec

  • 18

    Mar

DUK

Duke Energy

$87.77

-0.31 (-0.35%)

14:32
12/18/18
12/18
14:32
12/18/18
14:32
Hot Stocks
Former Duke Energy chairman and CEO Jim Rogers dies »

Jim Rogers, the former…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFMS

Conformis

$0.45

-0.0215 (-4.54%)

14:31
12/18/18
12/18
14:31
12/18/18
14:31
Hot Stocks
Conformis enters common stock purchase agreement with Lincoln Park Capital Fund »

Conformis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDC

First Data

$16.60

0.18 (1.10%)

14:30
12/18/18
12/18
14:30
12/18/18
14:30
Options
Hefty call spreads in First Data for the second time in three trading days »

Hefty call spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

BIIB

Biogen

$293.35

-19.87 (-6.34%)

, MYL

Mylan

$29.02

0.17 (0.59%)

14:29
12/18/18
12/18
14:29
12/18/18
14:29
Recommendations
Biogen, Mylan analyst commentary  »

Piper says Biogen…

BIIB

Biogen

$293.35

-19.87 (-6.34%)

MYL

Mylan

$29.02

0.17 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APEN

Apollo Endosurgery

$3.57

0.08 (2.29%)

14:27
12/18/18
12/18
14:27
12/18/18
14:27
Recommendations
Apollo Endosurgery analyst commentary  »

Craig-Hallum says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:20
12/18/18
12/18
14:20
12/18/18
14:20
General news
Canada CPI preview »

Canada CPI preview:…

TCEHY

Tencent

$0.00

(0.00%)

, DIS

Disney

$109.75

-0.88 (-0.80%)

14:18
12/18/18
12/18
14:18
12/18/18
14:18
Periodicals
'PUBG' on mobile has as many total users as 'Fortnite,' Verge reports »

The mobile version of…

TCEHY

Tencent

$0.00

(0.00%)

DIS

Disney

$109.75

-0.88 (-0.80%)

KKR

KKR

$19.89

0.09 (0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 11

    Feb

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
12/18/18
12/18
14:17
12/18/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
12/18/18
12/18
14:16
12/18/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$6.72

-0.39 (-5.49%)

14:05
12/18/18
12/18
14:05
12/18/18
14:05
Options
McDermott call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$163.24

-0.19 (-0.12%)

14:02
12/18/18
12/18
14:02
12/18/18
14:02
Hot Stocks
General Dynamics unit awarded Department of Education contract »

General Dynamics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

APHA

Aphria

$5.87

0.43 (7.90%)

, TLRY

Tilray

$76.52

10.63 (16.13%)

14:00
12/18/18
12/18
14:00
12/18/18
14:00
Hot Stocks
Citron touts cannabis name Aphria again, sees shares above $8 by year-end »

Shares of Aphria (APHA)…

APHA

Aphria

$5.87

0.43 (7.90%)

TLRY

Tilray

$76.52

10.63 (16.13%)

ACB

Aurora Cannabis

$5.57

0.03 (0.54%)

MO

Altria Group

$51.40

-0.97 (-1.85%)

NVS

Novartis

$85.56

-0.24 (-0.28%)

CRON

Cronos Group

$11.50

0.375 (3.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

  • 07

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.